Asabys Partners
VC Fund
Barcelona, Spain
Asabys Partners is a venture capital firm that invests across the board in human healthcare. The company is active in the health-tech and biopharma industries and aims to invest in Spain and abroad in innovative and transformative technologies. Asabys Partners are motivated by the idea of pushing the boundaries of science and medicine. This is donethrough the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 50%
- Fund size:
- $117M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Asabys Partners invests in
Stages Asabys Partners invests in
Countries Asabys Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $1.3M–$13M
- Series A
- $7M–$57M
- Series B
- $18M–$135M
Investment Focus
Industry
- Health Care 12 (32%)
- Biotechnology 12 (32%)
- Medical Device 10 (26%)
- Medical 7 (18%)
- Pharmaceutical 5 (13%)
Stage
- Series A 10 (26%)
- Series B 8 (21%)
- Seed 5 (13%)
- Series C 3 (8%)
- Funding Round 2 (5%)
Country
- Spain 13 (34%)
- France 2 (5%)
- Belgium 2 (5%)
- Germany 1 (3%)
- Iceland 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Clara Campas Moya
Managing Partner and co-founder
|
Managing Partner and co-founder | Total investments: 11 | Find email | |
Montserrat Vendrell
Partner
|
Partner | Total investments: 1 | Find email | |
Nuria Aloy
CFO
|
CFO | Total investments: 0 | Find email | |
Josep Sanfeliu
Managing Partner and Co-Founder
|
Managing Partner and Co-Founder | Total investments: 13 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ona Therapeutics
|
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $86.6M / Series B / Jun 04, 2026 | |
Orikine Bio
|
Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders. | $3.2M / Seed / Feb 02, 2026 | |
Oriva Therapeutics
|
Oriva Therapeutics is a women's health company that treats chronic conditions affecting women. | Pre-Seed / Jan 22, 2026 | |
Qida
|
Qida is a home care company that offers expert, personalized, and humane in-home care for elderly or dependent people. This procedure is carried out in accordance with the Individualized Work Plan (PTI), a comprehensive plan that incorporates the major international assessment scales in the health and social fields. Qida is a social impact entitythat selects the best caregiver and also accompanies the person cared for and their family throughout the process through the figure of the Social Reference. | $42.5M / Series B / Nov 04, 2025 | |
|
Ona Therapeutics
|
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $11.6M / Venture - Series Unknown / Oct 09, 2025 | |
SafeHeal
|
SafeHeal is the first company created and incubated by MD Start, a medtech accelerator developing innovative medical devices based on inventions from physicians. It is currently funded by MD Start and Sofinnova Partners. SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition (Concours Mondial de l’Innovation - Phases 1 and 2) andof the iLab grant program, which foster talent and bring out future champions of the French economy.SafeHeal was also elected as the most promising and innovative investor conference MedTech start-up at Biovision 2016, was a finalist for the global Medtech Innovator 2016 competition.Finally, SafeHeal is a 2016 recipient of the Charles Foix grant which rewards innovations aimed at improving the quality of life of elderly people. | $11.7M / Series C / Sep 10, 2025 | |
Splice Bio
|
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M / Series B / Jun 11, 2025 | |
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M / Series C / Apr 29, 2025 | |
Augustine Therapeutics
|
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | |
Quibim
|
Quibim, with headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading pharmaceutical companies and research teams. Partners use Quibim Precision®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy ofnovel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. We understand every body part. We speak human. | $50M / Series A / Jan 28, 2025 | |
| See all 38 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Asabys Partners invest in?
Asabys Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 38 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Asabys Partners's check size?
Asabys Partners typically joins rounds of $1.3M–$13M at Seed, $7M–$57M at Series A and $18M–$135M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Asabys Partners participates in.
How do I contact Asabys Partners?
Public channels for Asabys Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Asabys Partners?
The team at Asabys Partners includes Clara Campas Moya (Managing Partner and co-founder), Montserrat Vendrell (Partner) and Nuria Aloy (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
